AlfaVbeta3 Antagonists Based on a Central Benzoic Acid Scaffold

• Autorzy: Will D. , Breipohl G. , Gourvest J. , Ruxer J. , Doucet B. , Auberval M. , Baran R. , Gaillard M. , Gadek T. , Knolle J. , Stilz H. U. , Peyman A.
• Języki publikacji: EN

Abstrakty

EN

A series of novel, highly potent _v_3 antagonists based on a benzoic acid scaffold and containing an acylguanidine as an Arg-mimetic and sulfonamide side chains is described. The compounds are selective against the fibrinogen receptor _IIb_3 and they are capable of inhibiting bone resorption in vivo in a TPTX model of osteoporosis. Therefore the compounds are promising drug substances for the treatment of osteoporosis.

Słowa kluczowe

EN

peptidomimetics; structure-activity relationship; RGD analog

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2005
• Tom: Vol. 79 / nr 3
• Strony: 567--572
• Opis fizyczny: Bibliogr. poz. 13, rys.

Twórcy

autor

Will D.

autor

Breipohl G.

autor

Gourvest J.

autor

Ruxer J.

autor

Doucet B.

autor

Auberval M.

autor

Baran R.

autor

Gaillard M.

autor

Gadek T.

autor

Knolle J.

autor

Stilz H. U.

autor

Peyman A.

• Aventis Pharma Deutschland GmbH, D-65926 Frankfurt, Germany

Bibliografia

• 1.Hynes R.O., Cell 69, 11 (1992).
• 2.Xiong J-P, Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L. and Arnaout M.A., Science, 296(5565), 151 (2002).
• 3.Miller W.H., Keenan R.M., Willette R.N. and Lark M.W., Drug Discovery Today, 5, 397 (2000).
• 4.Hartman G.D. and Duggan M.L., Exp. Opin. Invest. Drugs, 9, 1281 (2000).
• 5.Peyman A., Weliner V., Knolle J., Stilz H.U., Breipohl G., Scheunemann K. H., Carniato D., Ruxer J.M., Gourvest J.F., Gadek T.R. and Bodary S., Bioorg. Med. Chem. Lett., 10, 179 (2000).
• 6.Peyman A., Gourvesl J.-F., Gadek T.R. and Knolle J., Angew. Chem. Int. Ed., 39, 2874 (2000).
• 7.Excellently reviewed by: Duggan M.H. and Hutchinson J. H., Exp. Opin. Ther. Patents, 10, I 367 (2000); Hölzemann G., IDrugs, 41(1), 72 (2001); Coleman PJ. and Duong L.T., Exp. Opin. Ther. Patents, 12(7), 1009 (2002).
• 8.Green I..J., Brierley V.H. and Humphries M.J., Biochem. Soc. Trans., 23, 505S (1995).
• 9.Peyman A., Scheunemann K.-H., Will D.W., Knolle J., Wehner V., Breipohl G., Stilz H. U., Carniato D., Ruxer J.-M., Gourvest J.Auberval M., Doucet B., Baron R., Gaillard M., Gadek T.R. and Bodary S., Bioorg. Med. Chem. Lett., 11(15), 2011 (2001).
• 10.Zaddi M., Datta U.K., Moonga B.S. and MacIntyre I.,.J Endocrinology, 126, 473 (1990).
• 11. Marguerie G.A., Plow E.F. and Edgington T.S., J. Biol. Chem., 254, 5357 (1979); Stilz H.U., Jablonka B., Just M., Knolle J., Paulus K.F. and Zoller G.,.J. Med. Chem., 39, 2118 (1996).
• 12. Fisher J.E., Caulfield M.P., Sato M., Quartuccio H.A., Gould R.J., Garsky V.M., Rodan G.A. and Rosenblatt M., Endocrinology, 132, 1411 (1993).
• 13. Present address of authors: Gerhard Breipohl, Coley Pharmaceuticals GmbH, Hlisabeth-Selbert- Strasse 9, D-40764 Langenfeld, Germany; Jean-Francois Gourvest and Marline Gaillard, Avcntis Pharma France, 13, quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex, France; Bernard Doucet, Marielle Auberval and Roland Baron, ProSkelia, 102 Route dc Noisy, F-93235 Romainvillc Cedex, France; Jochen Knolle, Jerini AG, Invalidenstr. 130; 10115 Berlin, Germany.